Kodiak Sciences (NASDAQ:KOD – Get Free Report) released its earnings results on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.06, Zacks reports.
Kodiak Sciences Trading Up 1.7 %
Shares of NASDAQ KOD opened at $3.06 on Friday. Kodiak Sciences has a 12-month low of $2.19 and a 12-month high of $11.60. The company has a market cap of $161.03 million, a PE ratio of -0.84 and a beta of 2.26. The stock has a 50 day simple moving average of $4.93 and a 200-day simple moving average of $5.40.
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, December 9th.
Kodiak Sciences Company Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
See Also
- Five stocks we like better than Kodiak Sciences
- The How And Why of Investing in Oil Stocks
- Microsoft’s Big Malaysia Bet Could Pay Off for Investors
- Upcoming IPO Stock Lockup Period, Explained
- The 5 Most Oversold Stocks on the Market Are…
- What is the Australian Securities Exchange (ASX)
- Archer Aviation Stock Sees Surge in Institutional Buys
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
